Clinical effect of recombinant human prourokinase on patients with STEMI and its influence on blood flow classification and cardiac function
Objective To investigate the clinical efficacy of recombinant human prourokinase(rhPro-UK)in the treatment of ST-segment elevation myocardial infarction(STEMI).Methods A total of 60 STEMI patients treated in our hospital from September 2020 to April 2022 were randomly divided into an observation group and a control group,with 30 cases in each group.Both groups received percutaneous coronary intervention(PCI),with the control group receiving tirofiban treatment and the observation group receiving rhPro-UK combined with tirofiban.The TIMI blood flow grade,cardiac function indicators,myocardial injury markers,incidence of major adverse cardiovascular events(MACE),and adverse reactions were compared between the two groups.Results After treatment,the TIMI grade,cardiac function indicators,and myocardial injury markers were significantly better in the observation group compared to the control group,with statistically significant differences between the groups(t=2.915,3.170,3.352,4.803,9.160,6.387,all P＜0.05).The incidence of MACE during follow-up was lower in the observation group than in the control group,with a statistically significant difference(x2=5.192,P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups(X2=0.351,P＞0.05).Conclusion The application of rhPro-UK in PCI treatment for STEMI patients has significant clinical value,as it can improve TIMI blood flow grade,enhance cardiac function,reduce the extent of myocardial injury,and lower the risk of long-term MACE.
Myocardial infarctionInterventional therapyRecombinant human prourokinaseTirofibanCardiac function
万方数据
维普
